2-氯-3,5-二氟苯胺 | 36556-60-2

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯胺系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3,5-二氟苯胺
• 中文别名: 3,5-二氟-2-氯苯胺
• 英文名称: 2-chloro-3,5-difluoroaniline
• 英文别名: 2-Chlor-3,5-difluoranilin
• CAS: 36556-60-2
• 化学式: C₆H₄ClF₂N
• mdl: MFCD00134427
• 分子量: 163.554
• InChiKey: XDHOQZCRADUDRI-UHFFFAOYSA-N

物化性质

• 熔点：
  26-28
• 沸点：
  208.3±35.0 °C(Predicted)
• 密度：
  1.434
• 闪点：
  92

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22
• 海关编码：
  2921420090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 安全说明：
  R23,R26,R45,R36/37/39
• 储存条件：
  室温条件下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-3,5-difluoroaniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-3,5-difluoroaniline
CAS number: 36556-60-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4ClF2N
Molecular weight: 163.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3,5-二氟苯胺 在 硼烷四氢呋喃络合物 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists

  摘要：

  A series of tetrahydroquinoline derivatives were synthesized and profiled for their ability to act as glucocorticoid receptor selective modulators. Structure-activity relationships of the tetrahydroquinoline B-ring lead to the discovery of orally available GR-selective agonists with high in vivo activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.093
• 作为产物：
  描述：

  1-氯-2,4,6-三氟苯 以 甲醇 为溶剂， 生成 2-氯-3,5-二氟苯胺
  参考文献：
  名称：

  Process for producing 3,5-difluoroaniline and derivative thereof

  摘要：

  公开了一种生产3,5-二氟苯胺化合物的简便方法，包括将氨基化剂与1,3,5-三氟苯化合物反应。

  公开号：

  US05510533A1

文献信息

• [EN] (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES<br/>[FR] (AZA)INDOLE, BENZOTHIOPHÈNE ET BENZOFURAN-3-SULFONAMIDES
  申请人：UCB PHARMA GMBH

  公开号：WO2018122232A1

  公开（公告）日：2018-07-05

  Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

  揭示了具有GPR17调节特性的磺胺类化合物，可用于治疗或预防各种中枢神经系统和其他疾病，特别是用于预防和治疗髓鞘疾病或紊乱。
• Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors
  作者：Chih-Shiang Chang、Vathan Kumar、Der-Yen Lee、Yeh Chen、Yu-Chieh Wu、Jing-Yan Gao、Po-Chen Chu

  DOI：10.2174/0929867328666210203204254

  日期：2021.9.8

  A growing body of evidence suggests that Hsp70, which is overexpressed in human breast tumors, plays a role in tumorigenesis and tumor progression in breast cancer as well as in its aggressive phenotypes. Hsp70 constitutes a potential therapeutic target in the treatment of this disease.

  We developed a new series of rhodacyanine-based Hsp70 inhibitors, represented by compounds 1 and 6, in which the cationic pyridin-1-ium or thiazol-3-ium ring of existing Hsp70 inhibitors (e.g., JG-40 and JG-98) was replaced by a corresponding benzo- fused N-heterocycle.

  Several lines of evidence suggest that these benzo-fused derivatives may exert their antitumor activities, in part, by targeting Hsp70. These putative inhibitors displayed differential antiproliferative efficacy against breast cancer cells (IC₅₀ as low as 0.25 μM) versus nontumorigenic MCF-10A breast epithelial cells (IC₅₀ ≥ 5 μM). This was correlated with the corresponding Hsp70 expression levels. Using a protein refolding assay, we confirmed that these agents effectively inhibited the chaperone activity of Hsp70. Moreover, these inhibitors effectively suppressed the expression of well-known oncogenic client proteins of Hsp70’s, including FoxM1, HuR, and Akt, which paralleled their antiproliferative efficacy. Supporting the established role of Hsp70 in regulating protein refolding, these derivatives induced autophagy, as manifested by the conversion of LC3B-I to LC3B-II. Notably, these putative Hsp70 inhibitors did not cause a compensatory elevation in Hsp90 expression, contrasting with the previously reported effects of Hsp90 inhibitors on Hsp70 upregulation.

  Together with the finding that compounds 1 and 6 showed improved microsomal stability, these results suggest the translational potential of these putative Hsp70 inhibitors to foster new strategies for cancer therapy. However, whether these benzo-fused rhodacyanines act on kinases or other targets remains unclear. It is currently under investigation.

  背景：越来越多的证据表明，在人类乳腺肿瘤中过度表达的Hsp70在乳腺癌的肿瘤发生和进展以及其侵袭性表型中发挥作用。Hsp70构成了治疗该疾病的潜在治疗靶点。 方法：我们开发了一系列基于罗达氰基的Hsp70抑制剂，代表物为化合物1和6，其中现有Hsp70抑制剂（例如JG-40和JG-98）的阳离子吡啶-1-ium或噻唑-3-ium环被相应的苯并N-杂环取代。 结果：多条证据表明，这些苯并融合衍生物可能部分通过靶向Hsp70发挥其抗肿瘤活性。这些假定的抑制剂对乳腺癌细胞显示出不同的抗增殖效力（IC50低至0.25μM），而对非肿瘤性MCF-10A乳腺上皮细胞的IC50≥5μM。这与相应的Hsp70表达水平相关。通过蛋白质重折叠实验，我们确认这些药物有效地抑制了Hsp70的分子伴侣活性。此外，这些抑制剂有效地抑制了Hsp70的已知致癌客体蛋白，包括FoxM1、HuR和Akt的表达，这与它们的抗增殖效力相一致。支持Hsp70在调节蛋白质重折叠中的已知作用，这些衍生物诱导了自噬，表现为LC3B-I向LC3B-II的转化。值得注意的是，这些假定的Hsp70抑制剂不会引起Hsp90表达的补偿性升高，与先前报道的Hsp90抑制剂对Hsp70上调的效应形成对比。 结论：与化合物1和6显示出改善的微粒体稳定性的发现一起，这些结果表明这些假定的Hsp70抑制剂在促进癌症治疗新策略方面具有转化潜力。然而，这些苯并融合罗达氰是否作用于激酶或其他靶点仍不清楚，目前正在进行研究。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Cushing Timothy D.

  公开号：US20100331293A1

  公开（公告）日：2010-12-30

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、干燥综合征和自身免疫性溶血性贫血，包括各种过敏症状，本发明还提供了治疗与p110δ活性有关的、依赖于或与之相关的癌症的方法，包括但不限于白血病，如急性髓系白血病（AML）、髓增生异常综合征（MDS）、髓增生性疾病（MPD）、慢性髓性白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• Multinuclear half metallocene catalyst and method for preparing syndiotactic polystyrene using the same
  申请人：LG Chem Ltd.

  公开号：EP1777230A1

  公开（公告）日：2007-04-25

  Diclosed is a multinuclear transition metal half metallocene catalyst having a multinuclear half metallocene structure in which a transition metal of groups 3 to 10 on periodic table is connected to a cycloalkandienyl group or its derivative group on a side and also connected to phenol or phenolamine compound having a plurality of binding sites on another side. The metallocene catalyst is useful to produce syndiotatic styrene polymer having superior steroreguality, high melting point and broad molecular weight distribution with high activity together with a small amount of a cocatalyst. Further disclosed is a method for preparing styrene polymers using the same catalyst.

  披露了一种多核过渡金属半茂金属烯催化剂，其具有多核半茂金属烯结构，其中周期表3至10族的过渡金属连接到一个环戊二烯基团或其衍生物基团一侧，并且连接到另一侧具有多个结合位点的酚或酚胺化合物。这种茂金属烯催化剂可用于生产具有优越的立体构型、高熔点和宽分子量分布的顺反式苯乙烯聚合物，同时还需要少量的共催化剂。还公开了一种使用相同催化剂制备苯乙烯聚合物的方法。
• Process for producing 3,5-difluoraniline
  申请人：Ishihara Sangyo Kaisha Ltd.

  公开号：US05399767A1

  公开（公告）日：1995-03-21

  A process for producing 3,5-difluoroaniline, which comprises reacting a benzonitrile compound of the formula (I): ##STR1## wherein each of X.sub.1, X.sub.2 and X.sub.3 is hydrogen, chlorine, bromine or a cyano group, provided that at least one of X.sub.1 to X.sub.3 is a cyano group, with a mineral acid for hydrolysis and decarboxylation to obtain an aniline compound of the formula (II): ##STR2## wherein each of X.sub.4, X.sub.5 and X.sub.6 is hydrogen, chlorine or bromine, provided that at least one of X.sub.4 to X.sub.6 is hydrogen, and in the case of a compound of the formula (II) wherein X.sub.4, X.sub.5 and X.sub.6 are not simultaneously hydrogen, reacting such a compound with hydrogen in a presence of a catalyst for reduction to obtain 3,5 -difluoroaniline.

  一种制备3,5-二氟苯胺的方法，包括将式(I)的苯腈化合物反应与矿酸进行水解和脱羧，以获得式(II)的苯胺化合物，其中X1、X2和X3中的每个是氢、氯、溴或氰基，但至少一个是氰基；X4、X5和X6中的每个是氢、氯或溴，但至少一个是氢，如果式(II)的化合物中X4、X5和X6不同时为氢，则在还原催化剂的存在下将这种化合物与氢反应，以获得3,5-二氟苯胺。